Ionis Pharmaceuticals

FDA

ALS

tofersen

JPM23: Ionis CEO admits PCSK9 ship captained by Big Pharmas may have sailed

Fierce Biotech

Wed, 01/11/23 - 11:02 pm

ION449

Ionis gets into gene editing

EP Vantage

Mon, 11/14/22 - 10:39 am

Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting

gene editing

Metagenomi

Yahoo Finance

Sun, 11/13/22 - 06:59 pm

As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data

Endpoints

Mon, 11/7/22 - 05:24 pm

Roche

Ionis to build new manufacturing site in Southern California, doubling the size of its current site

IONIS-FB-LRx

kidney disease

Endpoints

Thu, 10/13/22 - 11:55 pm

drug manufacturing

California

PCSK9 pipeline shows signs of saturation

EP Vantage

Tue, 09/27/22 - 10:21 am

ION449

Novartis

Leqvio

PCSK9 inhibitors

AstraZeneca dumps Ionis drug despite hit in phase 2 cholesterol trial

Fierce Biotech

Fri, 09/23/22 - 11:00 am

ION449

cholesterol

Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease

Fierce Biotech

Wed, 09/7/22 - 10:18 am

Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant

Fierce Biotech

Thu, 07/28/22 - 05:54 pm

Bayer

kidney disease

Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen

fesomersen

Yahoo Finance

Wed, 07/20/22 - 09:31 am

cardiovascular disease

pelacarsen

Ionis hands off an antisense drug for kidney disease, giving all rights to Roche

Endpoints

Mon, 07/11/22 - 06:23 pm

Roche

IONIS-FB-LRx

immunoglobin A nephropathy

kidney disease

After phase 3 fail, Biogen posts 12-month data cut to make case for ALS prospect

Fierce Biotech

Fri, 06/3/22 - 09:16 am

Ionis, AstraZeneca change a key trial, fueling more questions about a genetic heart disease

BioPharma Dive

Mon, 05/2/22 - 11:03 am

transthyretin amyloid cardiomyopathy

ACC 2022 – Astra’s cholesterol lowerer surprise comes just a little late

EP Vantage

Tue, 04/5/22 - 10:59 am

New blow for ALS pipeline as Biogen and Ionis candidate fails Phase 1 trial

Pharmaforum

Tue, 03/29/22 - 10:54 am

ALS

Pfizer ends $3B drug dream despite phase 2b success, leaving Regeneron with a clear run at cardiovascular market

BIIB078

Fierce Biotech

Mon, 01/31/22 - 10:47 am

Pfizer

vupanorsen

Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal Huntington's trial

cholesterol

Fierce Biotech

Tue, 01/18/22 - 10:30 am

Roche

tominersen

Huntington's disease

JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor

Fierce Biotech

Wed, 01/12/22 - 11:12 am

JPMHC 2022

BeiGene

Biogen brings in a successor to Spinraza

BioPharma Dive

Tue, 01/4/22 - 10:49 pm